# ALL Backbone in AYAs

> **NCT07227584** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Dana-Farber Cancer Institute** · enrollment: 67 (estimated)

## Conditions studied

- Acute Lymphoblastic Leukemia
- Philadelphia Chromosome-Negative Lymphoblastic Leukemia
- Acute Lymphoblastic Leukemia (ALL)
- Leukemia

## Interventions

- **DRUG:** Blinatumomab
- **DRUG:** Oncaspar
- **DRUG:** Cyclophosphamide
- **DRUG:** Cytarabine
- **DRUG:** Dexamethasone
- **DRUG:** Doxorubicin Hydrochloride
- **DRUG:** Etoposide
- **DRUG:** Mercaptopurine
- **DRUG:** Methotrexate
- **DRUG:** Vincristine

## Key facts

- **NCT ID:** NCT07227584
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2030-07-31
- **Final completion:** 2035-07-31
- **Target enrollment:** 67 (ESTIMATED)
- **Last updated:** 2025-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07227584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07227584, "ALL Backbone in AYAs". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07227584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*